All Stories

  1. Immunophenotypic portrait of leukemia‐associated‐phenotype markers in B acute lymphoblastic leukemia
  2. Extreme thrombocytosis with an aggressive evolution harboring a novel variant of calreticulin (CALR) in exon 3
  3. EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma
  4. S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability in multiple myeloma
  5. MRE11 and TREX1 control senescence by coordinating replication stress and interferon signaling
  6. Var∣Decrypt: a novel and user-friendly tool to explore and prioritize variants in whole-exome sequencing data
  7. 3-O sulfation of syndecan-1 mediated by the sulfotransferase HS3ST3a1 enhances myeloma aggressiveness
  8. Editorial: Transcriptional control in normal and malignant B-lymphocytes
  9. LAIR1, an ITIM-Containing Receptor Involved in Immune Disorders and in Hematological Neoplasms
  10. The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance
  11. Var|Decrypt: a novel and user-friendly tool to explore and prioritize variants in whole-exome sequencing data
  12. Inhibition of the Protein Arginine Methyltransferase PRMT5 in High-Risk Multiple Myeloma as a Novel Treatment Approach
  13. Single-hit genome edition for expression of single-chain immunoglobulins by edited B cells
  14. PIM2 kinase has a pivotal role in plasmablast generation and plasma cell survival, opening up novel treatment options in myeloma
  15. Targeting Cellular Iron Homeostasis with Ironomycin in Diffuse Large B-cell Lymphoma
  16. The NADPH oxidase NOX2 is a marker of adverse prognosis involved in chemoresistance of acute myeloid leukemias
  17. Comprehensive characterization of the epigenetic landscape in Multiple Myeloma
  18. Angiogenic factors could help us to define patients obtaining complete response with undetectable minimal residual disease in untreated CLL patients treated by FCR: results from the CLL2010FMP, a FILO study
  19. The microenvironment of DLBCL is characterized by noncanonical macrophages recruited by tumor-derived CCL5
  20. RNA-Sequencing-Based Transcriptomic Score with Prognostic and Theranostic Values in Multiple Myeloma
  21. Targeting the methyltransferase SETD8 impairs tumor cell survival and overcomes drug resistance independently of p53 status in multiple myeloma
  22. Transcription/Replication Conflicts in Tumorigenesis and Their Potential Role as Novel Therapeutic Targets in Multiple Myeloma
  23. Clinical Correlations of Polycomb Repressive Complex 2 in Different Tumor Types
  24. Discovery of Candidate DNA Methylation Cancer Driver Genes
  25. G9a/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor–mediated cell death
  26. RNA-sequencing data-driven dissection of human plasma cell differentiation reveals new potential transcription regulators
  27. Immunotherapy perspectives in the new era of B-cell editing
  28. The NADPH oxidase NOX2 is a marker of adverse prognosis involved in chemoresistance of Acute Myeloid Leukemias
  29. The origin of preplasmablastic cells
  30. Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma
  31. Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma
  32. Targeting DNA Repair to Overcome Drug Resistance in Hodgkin Lymphoma
  33. Role of Polycomb Complexes in Normal and Malignant Plasma Cells
  34. DNA Repair Expression Profiling to Identify High-Risk Cytogenetically Normal Acute Myeloid Leukemia and Define New Therapeutic Targets
  35. A Retrospective Comparison of DLI and gDLI for Post-Transplant Treatment
  36. Correction to: Characterization of immortalized human islet stromal cells reveals a MSC-like profile with pancreatic features
  37. Characterization of immortalized human islet stromal cells reveals a MSC-like profile with pancreatic features
  38. Dihydropyrimidinase protects from DNA replication stress caused by cytotoxic metabolites
  39. Anticorps anti-CD38 dans le myélome multiple
  40. Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma
  41. Prediction of Malingant Plasma Cell Biology Related Survival in AL-Amyloidosis
  42. Targeting the methyltransferase SETD8 impairs tumor cell survival and overcomes drug resistance independently of p53 status in multiple myeloma
  43. Treatment May Be Harmful: Mechanisms/Prediction/Prevention of Drug-Induced DNA Damage and Repair in Multiple Myeloma
  44. Phenotypic Characterization of Diffuse Large B-Cell Lymphoma Cells and Prognostic Impact
  45. Kinome expression profiling to target new therapeutic avenues in multiple myeloma
  46. Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial
  47. The hydroxymethylome of multiple myeloma identifies FAM72D as a 1q21 marker linked to proliferation
  48. Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (ATR) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer
  49. The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma
  50. Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells
  51. Overexpression of Claspin and Timeless protects cancer cells from replication stress in a checkpoint-independent manner
  52. EZH2 is overexpressed in transitional preplasmablasts and is involved in human plasma cell differentiation
  53. Myeloid-derived suppressor cells induce multiple myeloma cell survival by activating the AMPK pathway
  54. In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
  55. Characterization of the mutational landscape in multiple myeloma cell lines
  56. BrdU incorporation in multiparameter flow cytometry: A new cell cycle assessment approach in multiple myeloma
  57. PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs
  58. Dihydropyrimidinase protects from DNA replication stress caused by cytotoxic metabolites.
  59. Physiological and druggable skipping of immunoglobulin variable exons in plasma cells
  60. Rôle de EZH2 comme biomarqueur dans le traitement personnalisé du myélome multiple
  61. Tumor-associated neutrophils correlate with poor prognosis in diffuse large B-cell lymphoma patients
  62. GEP-based EpiScore predicts survival in patients with diffuse large B cell lymphoma
  63. DNMTi/HDACi induces reprogramming of myeloma cells in the direction of normal plasma cells
  64. Analysis of Global Gene Expression Profiles
  65. Loss of RASSF4 Promotes RAS-Driven Malignant Progression in MM
  66. CD24, CD27, CD36 and CD302 gene expression predict outcome in patients with multiple myeloma
  67. Automated and simplified identification of normal and abnormal plasma cells in Multiple Myeloma by flow cytometry
  68. Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion
  69. Characterization of human FCRL4-positive B cells
  70. Hypoxia favors the generation of human plasma cells
  71. Global miRNA expression analysis identifies novel key regulators of plasma cell differentiation and malignant plasma cell
  72. RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma
  73. Forced KLF4 expression increases the generation of mature plasma cells and uncovers a network linked with plasma cell stage
  74. Differential effects of lenalidomide during plasma cell differentiation
  75. RECQ helicases are deregulated in hematological malignancies in association with a prognostic value
  76. Identifying high-risk adult AML patients: epigenetic and genetic risk factors and their implications for therapy
  77. Chetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myeloma
  78. Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells
  79. miRNAs in multiple myeloma – a survival relevant complex regulator of gene expression
  80. EZH2 in normal hematopoiesis and hematological malignancies
  81. Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma
  82. Drug metabolism and clearance system in tumor cells of patients with multiple myeloma
  83. In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma
  84. Expression and role of RIP140/NRIP1 in chronic lymphocytic leukemia
  85. SNaPshot as a Valuable Option for the Identification of Mutations in Myeloma
  86. The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cells
  87. DNA repair in diffuse large B-cell lymphoma: a molecular portrait
  88. Identification and characterization of new Leishmania promastigote surface antigens, LaPSA-38S and LiPSA-50S, as major immunodominant excreted/secreted components of L. amazonensis and L. infantum
  89. A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategy
  90. Identification of a 20-Gene Expression-Based Risk Score as a Predictor of Clinical Outcome in Chronic Lymphocytic Leukemia Patients
  91. The Glycome of Normal and Malignant Plasma Cells
  92. DNA methylation score is predictive of myeloma cell sensitivity to 5-azacitidine
  93. DNA repair pathways in human multiple myeloma
  94. Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors
  95. Nucleotide excision DNA repair pathway as a therapeutic target in patients with high-risk diffuse large B cell lymphoma
  96. Inhibition of DEPDC1A, a Bad Prognostic Marker in Multiple Myeloma, Delays Growth and Induces Mature Plasma Cell Markers in Malignant Plasma Cells
  97. Kruppel-like factor 4 blocks tumor cell proliferation and promotes drug resistance in multiple myeloma
  98. STEAP1 is overexpressed in cancers: A promising therapeutic target
  99. Gene expression-based risk score in diffuse large B-cell lymphoma
  100. Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma?
  101. Growth Factors in Multiple Myeloma
  102. Development of Gene Expression-Based Score to Predict Sensitivity of Multiple Myeloma Cells to DNA Methylation Inhibitors
  103. Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients
  104. Identification of Pluripotent and Adult Stem Cell Genes Unrelated to Cell Cycle and Associated with Poor Prognosis in Multiple Myeloma
  105. Clinical and prognostic role of annexin A2 in multiple myeloma
  106. Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells
  107. New prognostic markers, determined using gene expression analyses, reveal two distinct subtypes of chronic myelomonocytic leukaemia patients
  108. Efficient transduction of healthy and malignant plasma cells by lentiviral vectors pseudotyped with measles virus glycoproteins
  109. Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma
  110. SULFs in human neoplasia: implication as progression and prognosis factors
  111. The role of fluorescence in situ hybridization and gene expression profiling in myeloma risk stratification
  112. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines
  113. MYEOV is a prognostic factor in multiple myeloma
  114. Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration
  115. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma
  116. Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays
  117. Abstract 124: Involvement of the notch pathway in the clonogenicity of human multiple myeloma cell lines
  118. NPM1 is overexpressed in hyperdiploid multiple myeloma due to a gain of chromosome 5 but is not delocalized to the cytoplasm
  119. Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study
  120. Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis
  121. APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop
  122. Embryonic stem cell markers expression in cancers
  123. Induction of angiogenesis by normal and malignant plasma cells
  124. APRIL is overexpressed in cancer: link with tumor progression
  125. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor
  126. MMSET is overexpressed in cancers: Link with tumor aggressiveness
  127. Cytokine Pathways in Myeloma Growth and Survival
  128. Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma
  129. CD200: A putative therapeutic target in cancer
  130. Input of DNA Microarrays to Identify Novel Mechanisms in Multiple Myeloma Biology and Therapeutic Applications
  131. Targeting NF-κB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth
  132. TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines
  133. CD200 is a new prognostic factor in multiple myeloma
  134. P20. TACI-signalling in multiple myeloma – From the identification as potential therapeutic target by gene expression analysis and functional testing to clinical trials
  135. P43. ErbB-signalling in multiple myeloma – From the identification as potential therapeutic target by gene expression analysis and functional testing to clinical trials
  136. P21. A molecular classification of multiple myeloma (MM) based on gene expression profiling and fluorescence in situ hybridisation as independent prognostic factor for event free survival (EFS)
  137. Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma
  138. Microarray-based understanding of normal and malignant plasma cells
  139. Lymphocytes of dogs immunised with purified excreted-secreted antigens of Leishmania infantum co-incubated with Leishmania infected macrophages produce IFN gamma resulting in nitric oxide-mediated amastigote apoptosis
  140. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature
  141. Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells
  142. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone
  143. Survival and Proliferation Factors of Normal and Malignant Plasma Cells